XPO1 and myelodysplastic syndrome: Given the small sample size of the SF3B1 mutant MDS patients treated in clinical trials, we further investigated the relationship between XPO1 inhibition and splicing mutations using the BEAT AML 2.0 ex vivo sensitivity data [36].